THE LANCET Haematology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. *Lancet Haematol* 2020; published online April 9. https://doi.org/10.1016/S2352-3026(20)30109-5.

Supplemental Table 1. Laboratory findings of COVID-19 with high and low VTE risk

y results	Padua Score <4	Padua Score ≥ 4	OR (95%CI) *	P value*
	12.0(11.0-13.0)	12.0(11.0-13.0)		
>13.5	51/349(14.6%)	44/286(15.4%)	1.10 (0.69-1.77)	0.688
	32.0(28.0-36.0)	30.0(25.0-34.0)		
>37	74/345(21.4%)	45/277(16.2%)	0.81 (0.52-1.27)	0.364
	169.0(134.0-206.0)	167.0(126.0-211.3)		
<100	22/477(4.6%)	35/350(10.0%)	0.55 (0.31-1.00)	0.050
	25(20.3-34.0)	31.0(23.0-42.0)		
>40	74/414(17.9%)	90/313(28.8%)	1.63 (1.10-2.40)	0.014
	22.0(15.0-33.2)	26.0(17.1-40.9)		
>50	51/405(12.6%)	60/308(19.5%)	1.85 (1.18-2.89)	0.007
	0.3(0.2-0.8)	0.6(0.3-1.5)		
>1.5	43/294(14.6%)	58/249(23.3%)	1.41 (0.87-2.29)	0.169
	10.4(3.7-24.1)	23.7(9.3-54.6)		
>10	229/444(51.6%)	225/315(71.4%)	1.78 (1.27-2.48)	0.001
	>13.5 >37 <100 >40 >50 >1.5	12.0(11.0-13.0) >13.5 51/349(14.6%) 32.0(28.0-36.0) >37 74/345(21.4%) 169.0(134.0-206.0) <100 22/477(4.6%) 25(20.3-34.0) >40 74/414(17.9%) 22.0(15.0-33.2) >50 51/405(12.6%) 0.3(0.2-0.8) >1.5 43/294(14.6%) 10.4(3.7-24.1)	12.0(11.0-13.0) 12.0(11.0-13.0) >13.5 51/349(14.6%) 44/286(15.4%) 32.0(28.0-36.0) 30.0(25.0-34.0) >37 74/345(21.4%) 45/277(16.2%) 169.0(134.0-206.0) 167.0(126.0-211.3) <100 22/477(4.6%) 35/350(10.0%) 25(20.3-34.0) 31.0(23.0-42.0) >40 74/414(17.9%) 90/313(28.8%) 22.0(15.0-33.2) 26.0(17.1-40.9) >50 51/405(12.6%) 60/308(19.5%) 0.3(0.2-0.8) 0.6(0.3-1.5) >1.5 43/294(14.6%) 58/249(23.3%) 10.4(3.7-24.1) 23.7(9.3-54.6)	12.0(11.0-13.0) 12.0(11.0-13.0) >13.5 51/349(14.6%) 44/286(15.4%) 1.10 (0.69-1.77) 32.0(28.0-36.0) 30.0(25.0-34.0) >37 74/345(21.4%) 45/277(16.2%) 0.81 (0.52-1.27) 169.0(134.0-206.0) 167.0(126.0-211.3) <100 22/477(4.6%) 35/350(10.0%) 0.55 (0.31-1.00) 25(20.3-34.0) 31.0(23.0-42.0) >40 74/414(17.9%) 90/313(28.8%) 1.63 (1.10-2.40) 22.0(15.0-33.2) 26.0(17.1-40.9) >50 51/405(12.6%) 60/308(19.5%) 1.85 (1.18-2.89) 0.3(0.2-0.8) 0.6(0.3-1.5) >1.5 43/294(14.6%) 58/249(23.3%) 1.41 (0.87-2.29) 10.4(3.7-24.1) 23.7(9.3-54.6)

^{*} adjusted by age, # refers to the number of patients above or below the threshold stated in column 2, the threshold was selected based on the normal range of these laboratory results.